Perspective technologies for design of therapeutics

Antibiotiki i Khimioterapiya

Volumn 50, Issue 2-3, 2005, Pages 52-63

  Miller, G G ^a   Voronina, T A ^a  

^a NONE

Author keywords

Combinatorial libraries of chemical compounds; Gene therapy; Genomics; Proteonics; Small molecule compounds; Strategies for drug design

Indexed keywords

CHEMOKINE; CYTOCHROME P450; SUPEROXIDE DISMUTASE;

CHEMICAL STRUCTURE; COMBINATORIAL CHEMISTRY; COMPUTER SIMULATION; DRUG DESIGN; DRUG EFFECT; FACTUAL DATABASE; GENOMICS; HUMAN; METABOLISM; METHODOLOGY; PHARMACEUTICS; REVIEW; RNA INTERFERENCE; STRUCTURE ACTIVITY RELATION; TELOMERE;

CHEMOKINES; COMBINATORIAL CHEMISTRY TECHNIQUES; COMPUTER SIMULATION; CYTOCHROME P-450 ENZYME SYSTEM; DATABASES, FACTUAL; DRUG DESIGN; GENOMICS; HUMANS; MODELS, MOLECULAR; RNA INTERFERENCE; STRUCTURE-ACTIVITY RELATIONSHIP; SUPEROXIDE DISMUTASE; TECHNOLOGY, PHARMACEUTICAL; TELOMERE;

EID: 33644644979     PISSN: 02352990     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Agrafiotis D. K., Bone R. F., Saleme F. R. System, method and computer program for at least partially automatically generating chemical compounds having desired properties. US Patent 1997; 5: 584: 711.
2. Agrafiotis D. K., Bone R. F., Saleme F. R. System, method and computer program for at least partially automatically generating chemical compound having desired properties from a list of potential chemical compound to synthesize. Ibid; 1999; 5: 901: 069.
3. Agrafiotis D. K., Myslik J. C., Saleme F. R. Advances in diversity profiling and combinatorial series design. Mol Divers 1999; 4: 1-22.
4. Henke S.L. Superoxide dismutase mimics as future therapeutics. Exp Opin Therapeutics Patents 1999; 9: 169.
5. Agrafiotis D. K., Lobanov V. S., Rassochin D. N. et al. Virtual Screening for Bioactive Molecules /Bohm H.& Schneider G. eds. Weinheim, 2000; 265-300.
6. Russian source
7. Anzali S., Barnickel G., Cezanne B. et al. Computer prediction of activity spectra for substances (PASS) on the base of structure-activity relationships (SAR). J Med Chem 2001; 44: 15: 2432-2437.
8. Russian source
9. Russian source
10. Friedman S. H., DeCamp D., Sijbesma R. P. et al. Inhibition of the HIV-1 protease by fullerene derivatives: Model building studies and experimental verification. J Am Chem Soc 1993; 115: 6506-6509.
11. Russian source
12. Miller G. G., Romanova V. S., Kushch A. A. et al. New effective compounds for HIV proteinase inhibition. Antiv Res 2002; 53: 3: 25: A43.
13. Zlotnik A., Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121-127.
14. Schwartz T., Rosenkilde M. N. Is there a 'lock' for all agonist 'keys' in 7TM receptors? Trends Pharmacol Sci 1996; 17: 213-216.
15. Naya A. et al. Discovery of a novel CCR3 selective antagonist. Bioorgan Med Chem Lett 2001; 11: 1219-1223.
16. Tikola A. et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibition does not involve CXCR4 use. PNAS USA 2002; 99: 395-400.
17. Loetscher P., Moser B., Baggolini M. Chemokines and their receptors in lymphocytes traffic and HIV infection. Adv Immunol 2000; 74: 127-180.
18. Moiser D. E. et al. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus 1 inhibition in vitro. J Virol 1999; 73: 3544-3550.
19. Ortiz de Montellano P. R. Cytochrom P450: Structure, Mechanism and Biochemistry/ 2nd ed, New York, 1995.
20. Ito K., Iwatsubo T., Kanamitsu S. et al. Quantitative prediction of in vivo drug clearance and drug interaction from in vitro data on metabolism, together with bidding and transport. Ann Rev Pharmacol Toxicol 1998; 38: 461-499.
21. Rendic S., Di Carlo F. Human cytochrome P450 enzyme: a status report summurazing their reaction, substrates, inducers, and inhibitors. Drug Metabol Rev 1997; 29: 413-580.
22. Andersen J., Hutchinson C. Characterization of Sacharopolyspora erythreae cytochrome P450 genes and enzymes, including 6-deoxyerythronolide B hydroxylase. J. Bacteriol. 1992; 174: 725-735.
23. Chun Y.-J., Kim S., Kim D. et al. A new selective and potent inhibitor of human cytochrome P450 1 B 1 and its application to antimutagenesis. Cancer Res 2001; 61: 8164-8170.
24. cam: Substrate binding and catalysis. Biochemistry 2003; 32: 9355-9361.
25. Nakomura K. Martin M. V., Guendrich et al. Random mutagenesis of cytochrome P450 2A6 and screening with indole oxidation products. Arch Biochem & Biophys 2001; 395: 25-31.
26. Murdock D., Ensley B. D., Serdar C. et al. Construction of metabolic operons catalyzing the de novo biosynthesis of indigo in E.coli. Biotechnology 1993; 11: 381-386.
27. Salvemini D., Wang Z. -Q., Stern M. K. et al. Peroxynitric decompensation catalysis: novel therapeutics for peroxynitrite-mediated pathology. PNAS USA 1998; 95: 2659-2663.
28. Maxwells. R. Prospects for the use of antioxidant therapies. Drug; 1995: 49: 345-346.
29. Salvemini D., Riley D., Cuzzocrea S. Pharmacological manipulation of the inflammatory cascade by the superoxide dismutase mimetic M40403. Brit J Pharmacol 2001; 132: 815-827.
30. Russian source
31. Bearss D. J., Hurley L. H., Von Hoff D. D. Telomere maintenance mechanisms as a target for drug development., Oncogene 2000; 19: 6632-6641.
32. Me Eliott R., Wellinger R. J. The terminal DNA structure of mammalian chromosomes. EMBO J 1997; 16: 3705-3714.
33. Van Steensel B., de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature 1997; 385: 740-743.
34. Baumann P., Cech T. R. POT1, the putative telomer end-binding protein in fission yeast and humans. Science 2001; 292: 1171-1175.
35. Greider C. W., Blackburn E. H. Identification of a specific telomer terminal transferasa acting in Tetrahymena extracts. Cell 1985; 43: 405-413.
36. Kim N. V. Specific association of human telomerase activity with immortal cell and cancer. Science 1994; 266: 2011-2015.
37. Hahn W. C. et al. Inhibition of telomerase limits the growth of human cancer cells. Nature Med 1999; 10: 1164-1170.
38. Simonsson T., Henriksson M. C-Myc suppression in Burkitt's lymphoma cells. Biochem & Biophys Res Commun 2002; 290: 11-15.
39. Fire A. et al. Potent and specific genetic interference by double-stranded RNA in Caenorabditis elegans. Nature 1998; 391: 806-811.
40. Calpen N.J., Parrish S., Imani F. et al. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. PNAS USA 2001; 98: 9742-9747.
41. Vance V., Vancheret H. RNA silencing in plants defense and counterdefense. Science 2001; 292: 2277-2280.